Quantitative Growth Fraction Evaluation with MIB1 and Ki67 Antibodies in Breast Carcinomas

Barbareschi, Mattia; Girlando, Salvatore; Mauri, Francesca M.; Forti, Stefano; Eccher, Claudio; Mauri, Francesco; Togni, Roberto; Palma, Paolo Dalla; Doglioni, Claudio

doi:10.1093/ajcp/102.2.171

Cited by 86 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sections were stained immunohistochemically by the ABC method using either anti-myosin IIA mouse monoclonal antibody (clone ab24762, abcam, Cambridge, CB4 0FW, UK) (diluted 1 : 500) or anti-vimentin antibody (Dako Cytomation, Denmark A/S) (diluted 1 : 100) as the first antibody. After deparaffinisation, specimens were treated with 0.01% trypsin and an autoclave antigen retrieval system (Barbareschi et al, 1994). Sequentially, after inhibition of endogenous peroxidase activity with 0.5% hydrogen peroxide and incubation with 2% normal swine serum, the first antibody was applied.…”

Section: Database Searchesmentioning

confidence: 99%

Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy

et al. 2008

View full text Add to dashboard Cite

Although postoperative adjuvant chemotherapy (PAC) with uracil -tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy. Therefore, it is extremely important to identify patients for whom adjuvant chemotherapy will be beneficial. We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules. Furthermore, we carried out immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS. We detected two kinds of protein molecules (myosin IIA and vimentin) by LC-MS/MS. We confirmed their immunohistochemical expression and distribution, and evaluated the relationship between the expression of these proteins and prognosis after adjuvant chemotherapy. Patients with no expression of either myosin IIA or vimentin showed a significantly better outcome regardless of PAC using uracil -tegafur. However, we were unable to select responders to uracil -tegafur using these proteins. Cases of adenocarcinoma lacking expression of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment.

show abstract

Section: Database Searchesmentioning

confidence: 99%

Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…However, mitosis represents only a short phase in the active cell cycle, and accordingly, only 1-5% of all DNA-synthesizing cells is microscopically detectable (24). In recent years, MIB-1 (a true equivalent of Ki-67) has been proven to be the best proliferation marker for routine use in formalin-fixed and paraffin-embedded tissue sections (4,7,24). The present study was carried to investigate whether the proliferative activity represented by MIB-1 and the immunoreactivity of p27 Kip1 has prognostic value in nephroblastoma.…”

Section: Discussionmentioning

confidence: 99%

MIB-1 (KI-67) Proliferation Index and Cyclin-Dependent Kinase Inhibitor p27Kip1 Protein Expression in Nephroblastoma

Ghanem

Kwast

Sudaryo

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: A number of studies have indicated that the tumor proliferation marker MIB-1 and cell cycle inhibitor p27Kip1 expression are of prognostic importance in a variety of cancers. The present study was performed to evaluate the prognostic value of these molecules in Wilms' tumors.Experimental Design: MIB-1 and p27 Kip1 expressions were investigated by the means of immunohistochemical analysis of 62 Wilms' tumor. Patients were preoperatively treated by chemotherapeutic agents and had a mean follow-up of 5.7 years.Results: MIB-1 and p27 Kip1 were expressed in normal kidney tissues and in the three main components of Wilms' tumor, i.e., the blastemal, epithelial, and stromal cells. In Wilms' tumors, the percentage of MIB-1-positive cells in the blastema ranged between 0 and 42% (mean, 9.4%) and in the epithelial component between 0 and 53% (mean, 19.9%), with a significant difference (P < 0.01). The percentage of blastemal p27Kip1 -positive cells ranged between 3 and 85% (mean, 55.1%) and for the epithelial component between 1 and 87% (mean, 59%). There was a significant inverse relationship between blastemal MIB-1 and p27Kip1 expression in Wilms' tumor. Univariate analysis showed that blastemal MIB-1 and p27Kip1 expression were indicative for clinical progression and tumor-specific survival. In a multivariate analysis, blastemal MIB-1 and p27Kip1 protein expression proved to be an independent prognostic for clinical progression besides stage. Conclusions:It was concluded that both MIB-1-based proliferative activity and p27Kip1 protein expression in the blastema have prognostic impact in Wilms' tumor.

show abstract

“…Tumor proliferative activity has been studied for a variety of neoplasms (22)(23)(24)(25)(26)(27) and seems to provide important biologic information that correlates with tumor recurrence and patients' survival. In the present study, the MIB1 LI was higher in the squamous cell carcinoma component than in the TCV component.…”

Section: Discussionmentioning

confidence: 99%

Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma

2000

View full text Add to dashboard Cite

Squamous cell carcinoma of the thyroid (SCT) is an unusual neoplasm thought to arise as a primary tumor or as a component of an undifferentiated carcinoma. The role of p53 and Ki-67 as prognostic indicators in this type of tumor is not known. We studied eight cases of primary SCT. Three cases were analyzed for Ki-67 by immunohistochemistry and for p53 by immunohistochemistry and loss of heterozygosity. Seven patients were women, and one was a man (age range, 31 to 90 years). SCT were firm, were tan with areas of necrosis, and ranged in size from 2 to 8 cm. Histologically, they had islands of squamous cells with spindle cell areas (two of eight). In four of eight cases, SCT was associated with the tall cell variant of papillary carcinoma (TCV). Positive staining for p53 was seen in two of three cases, and in one of three the TCV was also positive for p53. Mean MIB1 labeling index was 30% and 17% in SCT and TCV, respectively. At the time of presentation, six of eight patients had cervical lymph node metastases. In one case, the primary tumor had SCT and TCV; however, only the SCT component metastasized. After mean follow-up of 48 months, one patient had died of disease, five were alive with recurrent or metastatic tumor, and two were lost to follow-up. Primary SCT is an aggressive neoplasm that may be found in association with TCV. p53 expression and high MIB1 labeling index occur in these tumors and may be useful prognosticators.KEY WORDS: Squamous cell carcinoma, Tall cell variant, Thyroid neoplasms.Mod Pathol 2000;13(7):742-746Squamous cell carcinoma of the thyroid gland (SCT) is an unusual tumor with only a few reported cases. According to classic literature, it is thought to arise in two settings: as a primary tumor or as a component of an anaplastic or undifferentiated thyroid carcinoma, often mixed with heterologous elements and usually associated with areas of welldifferentiated papillary or follicular carcinoma. The tall cell variant of papillary carcinoma (TCV), first described by Hawk and Hazard (1), is defined by the presence of neoplastic cells having a height that is at least twice the width in an otherwise typical papillary carcinoma. Several investigators found the TCV to have a more aggressive behavior than ordinary well-differentiated papillary carcinoma (2, 3).We and others (4) have noticed that most cases of SCT are associated with TCV. However, it is not known whether the presence of an SCT component connotes a worse prognosis. In addition, the role of p53 and Ki-67 expression in these tumors is not known.In the present study, we reviewed the histologic features of our cases of SCT and investigated whether detection of p53 tumor suppressor gene and Ki-67 antigen by immunohistochemistry and loss of heterozygosity (LOH) analysis are helpful prognosticators. MATERIALS AND METHODSEight cases of primary SCT were studied. Five of the cases were obtained by reviewing the surgical pathology material of more than 200 cases of thyroid carcinomas at the Laboratory of Pathology, National Institutes of Hea...

show abstract

Quantitative Growth Fraction Evaluation with MIB1 and Ki67 Antibodies in Breast Carcinomas

Cited by 86 publications

References 0 publications

Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy

Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy

MIB-1 (KI-67) Proliferation Index and Cyclin-Dependent Kinase Inhibitor p27Kip1 Protein Expression in Nephroblastoma

Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma

Contact Info

Product

Resources

About